argenx: FcRn Is Becoming an Autoimmune Operating System — Back the Platform, Not Just the Drug
argenx's FcRn platform (VYVGART and Hytrulo) is transitioning from a single blockbuster to a multi-indication backbone across neuromuscular and peripheral autoimmune diseases. FDA label expansion, strong Phase 3 readouts, and a clear commercial ramp argue for continued upside from today's $817 share price, but execution and competition keep risk el…